Bacterial Inclusion Bodies of Alzheimer's Disease β-Amyloid Peptides Can Be Employed To Study Native-Like Aggregation Intermediate States

ChemBioChem ◽  
2011 ◽  
Vol 12 (3) ◽  
pp. 407-423 ◽  
Author(s):  
Muralidhar Dasari ◽  
Alba Espargaro ◽  
Raimon Sabate ◽  
Juan Miguel Lopez del Amo ◽  
Uwe Fink ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Inclusion Bodies ◽  
Amyloid Peptides ◽  
Intermediate States ◽  
Β Amyloid

Statin treatment and a disease-specific pattern of β-amyloid peptides in Alzheimer’s disease

2005 ◽  
Vol 164 (2) ◽  
pp. 205-214 ◽  
Author(s):  
Kina Höglund ◽  
Steinar Syversen ◽  
Piotr Lewczuk ◽  
Anders Wallin ◽  
Jens Wiltfang ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Statin Treatment ◽  
Specific Pattern ◽  
Amyloid Peptides ◽  
Β Amyloid ◽  
Disease Specific

scholarly journals Paper-Based Detection Device for Alzheimer’s Disease—Detecting β-amyloid Peptides (1–42) in Human Plasma

Diagnostics ◽  
2020 ◽  
Vol 10 (5) ◽  
pp. 272
Author(s):  
Wei-Hsuan Sung ◽  
Jung-Tung Hung ◽  
Yu-Jen Lu ◽  
Chao-Min Cheng
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Operating Time ◽  
Amyloid Peptide ◽  
Buffer System ◽  
Amyloid Peptides ◽  
Β Amyloid ◽  
Β Amyloid Peptide ◽  
Short Operating Time ◽  
Tremendous Impact

The diagnosis of Alzheimer’s disease (AD) is frequently missed or delayed in clinical practice. To remedy this situation, we developed a screening, paper-based (P-ELISA) platform to detect β-amyloid peptide 1–42 (Aβ42) and provide rapid results using a small volume, easily accessible plasma sample instead of cerebrospinal fluid. The protocol outlined herein only requires 3 μL of sample per well and a short operating time (i.e., only 90 min). The detection limit of Aβ42 is 63.04 pg/mL in a buffer system. This P-ELISA-based approach can be used for early, preclinical stage AD screening, including screening for amnestic mild cognitive impairment (MCI) due to AD. It may also be used for treatment and stage monitoring purposes. The implementation of this approach may provide tremendous impact for an afflicted population and may well prompt additional and expanded efforts in both academic and commercial communities.

Alternative pathways for production of β-amyloid peptides of Alzheimer's disease

2008 ◽  
Vol 0 (ja) ◽  
pp. 080808070126964-37 ◽  
Author(s):  
Vivian Hook ◽  
Israel Schechter ◽  
Hans-Ulrich Demuth ◽  
Gregory Hook
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Amyloid Peptides ◽  
Alternative Pathways ◽  
Β Amyloid

Mechanism and prevention of neurotoxicity caused by β-amyloid peptides: relation to Alzheimer's disease

1997 ◽  
Vol 776 (1-2) ◽  
pp. 40-50 ◽  
Author(s):  
Barbara J Blanchard ◽  
Genevieve Konopka ◽  
Margaret Russell ◽  
Vernon M Ingram
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Amyloid Peptides ◽  
Β Amyloid

scholarly journals Novel Detox Gel Depot Sequesters β-Amyloid Peptides in a Mouse Model of Alzheimer’s Disease

2011 ◽  
Vol 18 (2) ◽  
pp. 99-106 ◽  
Author(s):  
Ranjini K. Sundaram ◽  
Chinnaswamy Kasinathan ◽  
Stanley Stein ◽  
Pazhani Sundaram
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Mouse Model ◽  
Amyloid Peptides ◽  
Model Of Alzheimer’S Disease ◽  
Β Amyloid

β-Amyloid peptides display protective activity against the human Alzheimer’s disease-associated herpes simplex virus-1

2014 ◽  
Vol 16 (1) ◽  
pp. 85-98 ◽  
Author(s):  
Karine Bourgade ◽  
Hugo Garneau ◽  
Geneviève Giroux ◽  
Aurélie Y. Le Page ◽  
Christian Bocti ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Protective Activity ◽  
Herpes Simplex Virus 1 ◽  
Amyloid Peptides ◽  
Β Amyloid ◽  
Simplex Virus
Sign in / Sign up

Export Citation Format

Share Document